

Date: 12/8/2025

Massachusetts Life Sciences Center
1075 Main Street, Suite 100
Waltham, MA 02451

Dear MLSC Review Committee,

I am writing to express our strong interest in utilizing the proposed ARC Boston Research Infrastructure as part of our participation in the ARC Boston Accelerator. As a healthcare technology company specializing in 3D-printed, patient-specific instrumentation, our team will be physically based at the ARC Boston site and will directly benefit from the equipment, facilities, and shared research capabilities described in the application.

1. Commitment to Utilizing the Resource

We confirm that our company is fully committed to actively leveraging the research infrastructure supported by this grant, including:

- Dedicated office and workspace facilities
- High-performance computing resources for AI model development
- Prototyping and engineering tools, including a Form 4BL 3D-printing system with BioMed Durable materials
- Data analytics workstations
- Shared laboratory or simulation environments, as applicable
- Collaboration and testing spaces to support iterative development
- Access to subject-matter experts and local partners

2. Example of a Specific Project Using the Resource

CustoMED will conduct a proof of concept project with the Trauma Department at Massachusetts General Hospital in Boston to demonstrate the value of on demand, in clinic 3D printing of patient specific surgical guides for a wide range of trauma interventions, including complex fracture fixation and reconstructive procedures. During the project, custoMED's workflow will be integrated into existing clinical pathways, from imaging and case selection through guide design, validation, and same day production

in the hospital. The collaboration will measure key clinical and financial outcomes such as operative time, accuracy of fixation, complication and revision rates, length of stay, and total episode of care cost, to build robust evidence that custoMED's on site 3D printed guides improve patient outcomes while reducing overall treatment costs for the hospital

We believe that the ARC Boston Research Infrastructure will significantly accelerate our technical development, enhance collaboration with academic and clinical partners, and support our successful entry into the U.S. healthcare market.

Please feel free to contact me with any questions.

Sincerely,
Or Benifla
Founder & CEO
CustoMED

A handwritten signature in black ink, appearing to read 'Or Benifla', with a stylized, cursive script.

Date: 12/8/2025

Massachusetts Life Sciences Center
1075 Main Street, Suite 100
Waltham, MA 02451

Dear MLSC Review Committee,

I am writing to express our strong interest in utilizing the proposed ARC Boston Research Infrastructure as part of our participation in the ARC Boston Accelerator.

As a healthcare technology company focused on **building the first Emotion Brain Computer Interface (eBCI) for the treatment of severe mental illness**, our team will be physically located at the ARC Boston site in Boston and will directly utilize the equipment and shared research resources described in the application.

1. Commitment to Utilizing the Resource

We confirm that our company will actively use the equipment and research infrastructure provided through this grant, such as:

- Dedicated office space and facilities
- High-performance computing resources for AI model development
- Data analytics workstations
- Subject matter experts and local partners

2. Example of a Specific Project Using the Resource

We are launching a cutting-edge clinical trial in which we will treat the first Post Traumatic Stress Disorder (PTSD) patients. We will use our novel treatment to measure emotional codes, identify pathological emotional codes specific to the trauma, and recode the pathological codes to restore adaptive emotional response. As part of the study, we will map the brain activity at the neuronal level in response to our unique method of emotional provocation. We will use the unique acquired datasets to improve our state of the art classification algorithms. We utilize the most advanced AI tools and can benefit from data analytics workstations and high-performance computing resources.

In addition, our platform technology is suitable for various psychiatric indications. It was initially developed for PTSD, with strong proof of concept in an established PTSD model in non-human primates. As a next step, we plan to evaluate the selection of our first indication and analyze additional indications for regulatory and business considerations. We will need to conduct market research, speak to clinicians, patient groups, and regulatory and business experts, and will want to connect to subject matter experts and

local partners. We expect to be ready to start discussions with the FDA in Q3 2026 in order to identify the regulatory pathway and to apply for Breakthrough Device Designation (BDD) and Investigational Device Exemption (IDE).

We believe that the ARC Boston Research Infrastructure will significantly accelerate our technical development, enhance collaboration with academic and clinical partners, and support our successful entry into the U.S. healthcare market.

Please feel free to contact me with any questions.

Sincerely,



Dr. Dan Rappaport

Co-founder and CEO

Nuri Braintech Ltd.

נורי בריינטק בע"מ
NURI BRAINTECH LTD
ח.פ. 517122941

Date: 12/8/2025

Massachusetts Life Sciences Center
1075 Main Street, Suite 100
Waltham, MA 02451

Dear MLSC Review Committee,

I am writing to express our strong interest in utilizing the proposed ARC Boston Research Infrastructure as part of our participation in the ARC Boston Accelerator.

As a healthcare technology company focused on Precision Neuroscience, our team will be physically located at the ARC Boston site in Boston and will directly utilize the equipment and shared research resources described in the application.

1. Commitment to Utilizing the Resource

We confirm that our company will actively use the equipment and research infrastructure provided through this grant, such as:

- Dedicated office space and facilities
- High-performance computing resources for AI model development and MCX modeling of brain – light interaction.
- Prototyping tools and engineering equipment, such as:
 - In-vitro research tools such as MEA electrophysiology from cell culture, slices and 3D human neurons organoids.
 - BCI illumination device engineering tools for in-vivo and ex-vivo as well as testing, verification and validation systems for clinical devices. These tools include optical rigs (Laser/Led) and optical fiber processing, electronics and software development tools (e.g. for closed loop activation protocols), 3D printing for device design, as well as biocompatibility testing including hermetic sealing, accelerated aging testing, etc.
 - Surgical tools and procedures development tools, such as OR compatibility, fluoroscopy compatibility, surgeon usability, etc.
- Data analytics workstations
- Shared lab or simulation facilities (as applicable)
- Collaboration and testing environments (as applicable)
- Subject matter experts and local partners

2. Example of a Specific Project Using the Resource

Modulight Biotherapeutics is developing a novel, precision treatment modality for severe neurological disease, which is based on optogenetic modulation of specific neurons and pathway, associated with severe neural pathologies. As we are currently developing a system for the treatment of Trigeminal pain which involve outpatient surgical procedures for the delivery of the opsin and the illumination fiber, we will be able to utilize the unique ecosystem at ARC-Boston to design, test and validate these approaches and tools to apply them, through consultation with KOLs in the network, mechanically and electronically design of prototypes using specialized equipment in the lab, and test both in the lab and in the OR to make sure they meet standards and usability requirements.

The provided is one example out of several avenues of scientific, clinical, and business development processes which we find this ecosystem could support and boost dramatically for Modulight.

We believe that the ARC Boston Research Infrastructure will significantly accelerate our technical development, enhance collaboration with academic and clinical partners, and support our successful entry into the U.S. healthcare market.

Please feel free to contact me with any questions.

Sincerely,



Yotam Eldar, MD

CEO & Co-founder, Modulight Biotherapeutics

yotam@modulight.bio | www.modulight.bio

